Abstract: The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fragment crystallizable region (Fc) is an N-terminal of Immunoglobulin G (IgG); each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.

Abstract: The present invention provides antibodies that bind to CD47 with high affinity and specificity, and their use in treatment of a cancer.

Abstract: The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fragment crystallizable region (Fc) is an N-terminal of Immunoglobulin G (IgG); each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.

Abstract: A Myrmecridium flexuosum NUK-21, a novel lactose oxidase isolated from the Myrmecridium flexuosum NUK-21 and a method for conversion of lactose into lactobionic acid (LBA) by the novel lactose oxidase are disclosed herein. The Myrmecridium flexuosum NUK-21 produces high yields of the novel lactose oxidase and the novel lactose oxidase has higher reactivity and specificity of converting lactose into lactobionic acid.

Abstract: The present invention provides a bi-functional fusion protein simultaneously targeting the complement and the vascular endothelial growth factor (VEGF). The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting complement and VEGF related diseases.

Abstract: The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fc is an N-terminal of IgG; each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.

Abstract: A Myrmecridium flexuosum NUK-21, a novel lactose oxidase isolated from the Myrmecridium flexuosum NUK-21 and a method for conversion of lactose into lactobionic acid (LBA) by the novel lactose oxidase are disclosed herein. The Myrmecridium flexuosum NUK-21 produces high yields of the novel lactose oxidase and the novel lactose oxidase has higher reactivity and specificity of converting lactose into lactobionic acid.